At the recently held American Heart Rhythm Society (HRS）2025At the annual academic conference, the global medical device giant Medtronic (MDT) announced its pulsed field ablation (PFA) The latest clinical research data, under itsSphere-360Single-shotPFACatheter andSphere-9Combination Mapping/Dual-energy focusing catheter in atrial fibrillation (AFib) and ventricular tachycardia (VT) has shown significant efficacy in treatment,Marks the entry into electrophysiological interventional treatment“Precision and Efficiency”New Era.

The technical achievements released by Medtronic this time are based on its2022Year10Billion-dollar acquisition ofAfferaCore technology of the company. As the world's first to obtainFDAApproved for the treatment of atrial fibrillationPFASystem,PulseSelectThe platform integrates the following innovations:

Integrated 3D Electroanatomical Mapping:ThroughAfferaMapping system achieves real-time anatomical imaging of the heart and synchronized visualization of electrical signals, reducing operation planning time.40%；

Dual-Energy Ablation Catheter Design:Sphere-9Catheter Innovation Integrates Radiofrequency (RF) and pulsed field energy, which can dynamically switch ablation modes based on lesion characteristics, reducing the risk of esophageal thermal injury;

Breakthrough in Single Ablation Technology:Sphere-360The catheter adopts the world's smallest8.5FrSheath (Outer Diameter2.8mm), its34mmThe expandable lattice tip can complete pulmonary vein isolation in one step (PVI), reducing the number of catheter manipulations70%。

Sphere-360：Single Ablation for Long-TermPVI`, impressive safety data`，A prospective multicenter trial for paroxysmal atrial fibrillation showed,Sphere-360Catheter in12Achieved the following results during the month follow-up:

Durability of efficacy:88%Patients maintain sinus rhythm, with a recurrence rate lower than traditional radiofrequency ablation.35%；

Surgical Efficiency:Average Time Required for Bilateral Pulmonary Vein Isolation Using a Single Catheter18minutes, faster than the traditional multi-catheter approach60%；

Safety Validation:98%Target veins achieve permanent electrical isolation, with no serious adverse events reported in the optimized waveform treatment subgroup (SAE), complications such as esophageal fistula and phrenic nerve injury have been reduced to zero.

Director of the Arrhythmia Center at Mount Sinai Hospital in New YorkVivek ReddyThe doctor pointed out:“Sphere-360The lattice tip design overcomes the limitation of traditional catheters requiring repeated rotational positioning.‘Immediate Release’Significantly reduces the complexity of surgical procedures, especially suitable for beginners and patients with complex anatomical structures.”

For Persistent Atrial FibrillationSphere Per-AFSub-analysis revealed,Sphere-9Catheter in combinationPVI: Outstanding performance in linear ablation

Precision Ablation Capability:9mmThe tip of the nitinol cage can target ablation of complex areas such as the left atrial roof and mitral isthmus, with linear lesion continuity reaching97%；

Energy Synergy Effect:RF+PFADual-mode switching technology increases myocardial penetration depth compared to single-energy mode.2.3times, while controlling the esophageal surface temperature to38℃The following:

Clinical Endpoint Achievement:12Months Follow-up,72%Patients achieve sinus rhythm maintenance without antiarrhythmic drugs, compared to单纯的...PVIGroup Improvement18%。

Technological Breakthrough:Sphere-9The“Non-Rotational Ablation”Features solve the ablation blind spot issues of traditional catheters in anatomically distorted areas such as the mitral valve annulus. Its intelligent energy distribution algorithm can monitor tissue impedance in real time, automatically adjusting pulse parameters to prevent microbubble formation (reducing thrombosis risk).85%）。

Based on the currentPositive and forward-lookingResearch DataResults, Medtronic has launched the following strategic layout:

Sphere-360Key Trial: Planned for2025Year in the United States30Home-based randomized controlled trials (N=800), and compare its long-term efficacy with that of cryoballoon ablation;

VTTherapeutic Indications Expansion: UtilizationSphere-9RF Function Development for Ventricular Tachycardia Mapping-Ablation Integrated Solution,FDAGranted“Breakthrough Medical Device”Determination;

AISurgical Assistance System: IntegrationAfferaMapping Data andSphereCatheter Operation Log, Development of Automatic Arrhythmia Diagnosis and Ablation Path PlanningAIModule, Expected2026Entered clinical trials in the year.

With MedtronicPFAThe improvement of the technical matrix is driving profound changes in the electrophysiology market landscape.Analysis AgencyGlobalDataPredict, by2028Year GlobalPFAThe equipment market size will reach32billion dollars, of which Medtronic relies onSphereThe integrated advantages of the series catheter and mapping system are expected to capture40%The above share.

FromSphere-360The Single Ablation Revolution toSphere-9The Dual-Energy Synergistic Breakthrough, MedtronicAfferaTechnology platforms are redefining the standards for interventional treatment of arrhythmias. As key trials progress and indications expand,PFATechnology is expected to“Atrial Fibrillation-Specific Therapy”Upgraded to a full-scenario cardiac ablation solution, for global use3300Medtronic Brings Safer, More Efficient Treatment Options to Patients with Atrial Fibrillation.

(Source of data in this article:HRS 2025Annual Meeting Abstract, Medtronic Official Press Release,FDAMedical Device Database,GlobalDataIndustry Report)